Medigen Biotechnology Corp. (TPEX:3176)
Taiwan
· Delayed Price · Currency is TWD 33.65
+0.50 (1.51%)
Apr 29, 2026, 1:30 PM CST
Medigen Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,583 | 1,373 | 1,158 | 1,056 | 3,922 | Upgrade
|
| Revenue Growth (YoY) | 15.28% | 18.57% | 9.64% | -73.08% | 537.16% | Upgrade
|
| Cost of Revenue | 677.48 | 618.94 | 540.39 | 968.49 | 1,371 | Upgrade
|
| Gross Profit | 905.02 | 753.76 | 617.33 | 87.46 | 2,551 | Upgrade
|
| Selling, General & Admin | 558.15 | 571.21 | 499.64 | 402.31 | 376.61 | Upgrade
|
| Research & Development | 451.9 | 393.27 | 1,336 | 1,331 | 1,407 | Upgrade
|
| Other Operating Expenses | 47.3 | - | - | - | -1.36 | Upgrade
|
| Operating Expenses | 1,062 | 970.95 | 1,850 | 1,754 | 1,771 | Upgrade
|
| Operating Income | -156.99 | -217.2 | -1,233 | -1,667 | 779.96 | Upgrade
|
| Interest Expense | -23.12 | -36.39 | -55.86 | -39.45 | -19.07 | Upgrade
|
| Interest & Investment Income | 35.26 | 52.4 | 89.07 | 8.88 | 3.16 | Upgrade
|
| Earnings From Equity Investments | -43.08 | -28.44 | -92.26 | -262.21 | -98.8 | Upgrade
|
| Currency Exchange Gain (Loss) | -30.71 | 43.22 | -0.13 | 29.49 | 3.39 | Upgrade
|
| Other Non Operating Income (Expenses) | 8.57 | 5.24 | 24.03 | 74.31 | 457.12 | Upgrade
|
| EBT Excluding Unusual Items | -210.08 | -181.17 | -1,268 | -1,856 | 1,126 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.04 | -1.52 | -9.58 | -16.66 | 10.92 | Upgrade
|
| Gain (Loss) on Sale of Assets | -9.06 | 69.27 | -1.03 | - | -0.25 | Upgrade
|
| Other Unusual Items | 0.5 | 0.7 | - | 0 | - | Upgrade
|
| Pretax Income | -218.6 | -112.72 | -1,279 | -1,873 | 1,136 | Upgrade
|
| Income Tax Expense | 77.35 | 109.67 | 191.21 | 58.87 | 65.73 | Upgrade
|
| Earnings From Continuing Operations | -295.95 | -222.39 | -1,470 | -1,931 | 1,071 | Upgrade
|
| Net Income to Company | -295.95 | -222.39 | -1,470 | -1,931 | 1,071 | Upgrade
|
| Minority Interest in Earnings | 187.15 | 17.7 | 908.77 | 1,256 | -1,123 | Upgrade
|
| Net Income | -108.8 | -204.69 | -561.3 | -675.87 | -52.61 | Upgrade
|
| Net Income to Common | -108.8 | -204.69 | -561.3 | -675.87 | -52.61 | Upgrade
|
| Shares Outstanding (Basic) | 139 | 139 | 139 | 139 | 139 | Upgrade
|
| Shares Outstanding (Diluted) | 139 | 139 | 139 | 139 | 139 | Upgrade
|
| Shares Change (YoY) | - | -0.03% | 0.16% | 0.11% | -0.01% | Upgrade
|
| EPS (Basic) | -0.78 | -1.47 | -4.03 | -4.86 | -0.38 | Upgrade
|
| EPS (Diluted) | -0.78 | -1.47 | -4.03 | -4.86 | -0.38 | Upgrade
|
| Free Cash Flow | -30.9 | -16.93 | -541.93 | -1,286 | 375.16 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.12 | -3.89 | -9.25 | 2.70 | Upgrade
|
| Gross Margin | 57.19% | 54.91% | 53.32% | 8.28% | 65.05% | Upgrade
|
| Operating Margin | -9.92% | -15.82% | -106.51% | -157.87% | 19.89% | Upgrade
|
| Profit Margin | -6.88% | -14.91% | -48.48% | -64.01% | -1.34% | Upgrade
|
| Free Cash Flow Margin | -1.95% | -1.23% | -46.81% | -121.82% | 9.57% | Upgrade
|
| EBITDA | -8.95 | -66.3 | -1,078 | -1,498 | 967.36 | Upgrade
|
| EBITDA Margin | -0.56% | -4.83% | -93.11% | -141.83% | 24.66% | Upgrade
|
| D&A For EBITDA | 148.05 | 150.9 | 155.15 | 169.35 | 187.4 | Upgrade
|
| EBIT | -156.99 | -217.2 | -1,233 | -1,667 | 779.96 | Upgrade
|
| EBIT Margin | -9.92% | -15.82% | -106.51% | -157.87% | 19.89% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 5.78% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.